Trilogy Home Healthcare

trilogyhomehealthcare.com

Trilogy Home Healthcare is a Medicare certified home healthcare agency established by experienced industry leaders who have the passion for providing comprehensive in-home clinical care to our patients. Trilogy’s staff understands the importance of the relationship between the clinician, the patient and the physician with the common goal of patient recovery with positive outcomes and functional independence. Creating Solutions for Patients, Physicians, and our Community

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INDUSTRIAL IMPACT

WUXI XDC AND ABTIS SIGN MEMORANDUM OF UNDERSTANDING FOR DEVELOPMENT AND MANUFACTURING OF ANTIBODY DRUG CONJUGATES

WuXi Biologics | July 08, 2022

news image

WuXi XDC, a global leading CRDMO dedicated to end-to-end bioconjugates services, and AbTis, a Korean biotechnology company dedicated to the development of antibody drug conjugates announced that a Memorandum of Understanding was signed to form a strategic partnership in AbTis' portfolio of ADC products. Under the partnership, AbTis will have access to WuXi XDC's integrated services for linker and payload manufacturing, ADC conjugation process development, ADC formulation a...

Read More

INDUSTRY OUTLOOK

GENOMENON RECOGNIZED BY FROST & SULLIVAN FOR GENOMIC INTELLIGENCE SOLUTIONS AND SOFTWARE FOR PHARMA AND CLINICAL DIAGNOSTICS COMPANIES

prnewswire | May 08, 2023

news image

Frost & Sullivan announced that it has awarded Genomenon with the 2023 Global Technology Innovation Leadership Award. Each year, Frost & Sullivan presents this award to the company that has developed a product with innovative features and functionality that is gaining rapid acceptance in the market. The award recognizes the quality of the solution and the customer value enhancements it enables. Frost & Sullivan market analysts determined that Genomenon excels in many of the cri...

Read More

MEDICAL

INVENSHURE LAUNCHES MEKANISTIC THERAPEUTICS™

Invenshure | June 03, 2022

news image

Venture studio Invenshure announces the launch of MEKanistic Therapeutics, a biotechnology company redefining precision oncology. Co-inventors and pioneers in the MEK inhibitor field, Judith Sebolt-Leopold, PhD, and Christopher Whitehead, PhD, MBA, have rationally designed a drug that blocks two, key pathways (EGFR and PI3K) used to signal cancer cell growth, with a single molecule. In preclinical studies, this first-in-class dual inhibitor shows unparalleled tumor shrinkage without the toxicity...

Read More

MEDTECH

INSEMPRA ANNOUNCES STRATEGIC INVESTMENT IN SOLENA MATERIALS

Insempra, | July 26, 2022

news image

Insempra, a biology-powered company enabling businesses to make superior products in partnership with nature, today announces a strategic investment in Solena Materials Ltd a synthetic biology company. Solena, a spin-out from Imperial College London, develops synthetic proteins for high-performance clothing fibers. The investment will allow Insempra, formerly Origin.Bio, to accelerate its strategy of harnessing new technologies to advance biological production processes, creating ...

Read More
news image

INDUSTRIAL IMPACT

WUXI XDC AND ABTIS SIGN MEMORANDUM OF UNDERSTANDING FOR DEVELOPMENT AND MANUFACTURING OF ANTIBODY DRUG CONJUGATES

WuXi Biologics | July 08, 2022

WuXi XDC, a global leading CRDMO dedicated to end-to-end bioconjugates services, and AbTis, a Korean biotechnology company dedicated to the development of antibody drug conjugates announced that a Memorandum of Understanding was signed to form a strategic partnership in AbTis' portfolio of ADC products. Under the partnership, AbTis will have access to WuXi XDC's integrated services for linker and payload manufacturing, ADC conjugation process development, ADC formulation a...

Read More
news image

INDUSTRY OUTLOOK

GENOMENON RECOGNIZED BY FROST & SULLIVAN FOR GENOMIC INTELLIGENCE SOLUTIONS AND SOFTWARE FOR PHARMA AND CLINICAL DIAGNOSTICS COMPANIES

prnewswire | May 08, 2023

Frost & Sullivan announced that it has awarded Genomenon with the 2023 Global Technology Innovation Leadership Award. Each year, Frost & Sullivan presents this award to the company that has developed a product with innovative features and functionality that is gaining rapid acceptance in the market. The award recognizes the quality of the solution and the customer value enhancements it enables. Frost & Sullivan market analysts determined that Genomenon excels in many of the cri...

Read More
news image

MEDICAL

INVENSHURE LAUNCHES MEKANISTIC THERAPEUTICS™

Invenshure | June 03, 2022

Venture studio Invenshure announces the launch of MEKanistic Therapeutics, a biotechnology company redefining precision oncology. Co-inventors and pioneers in the MEK inhibitor field, Judith Sebolt-Leopold, PhD, and Christopher Whitehead, PhD, MBA, have rationally designed a drug that blocks two, key pathways (EGFR and PI3K) used to signal cancer cell growth, with a single molecule. In preclinical studies, this first-in-class dual inhibitor shows unparalleled tumor shrinkage without the toxicity...

Read More
news image

MEDTECH

INSEMPRA ANNOUNCES STRATEGIC INVESTMENT IN SOLENA MATERIALS

Insempra, | July 26, 2022

Insempra, a biology-powered company enabling businesses to make superior products in partnership with nature, today announces a strategic investment in Solena Materials Ltd a synthetic biology company. Solena, a spin-out from Imperial College London, develops synthetic proteins for high-performance clothing fibers. The investment will allow Insempra, formerly Origin.Bio, to accelerate its strategy of harnessing new technologies to advance biological production processes, creating ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us